Hybridization News and Research

RSS

New disposable, microfluidic PDMS device for identification of advanced breast cancer

A new disposable device based on advances in microfluidics may help identify advanced breast cancer patients who are candidates for therapy with the drug trastuzumab (Herceptin). The device is described in the American Institute of Physics' journal Biomicrofluidics.

29 Sep 2010

Catch by Gene enters agreement with C&S for HPV test kit

Catch by Gene has entered into an agreement to supply its reagent solutions to C&S Company Ltd commencing immediately in the initial amount of $300,000.

13 Sep 2010

Researchers identify two proteins in cellular response to mechanical stimulation

Scripps Research Institute scientists have identified two proteins with potential to be important targets for research into a wide range of health problems, including pain, deafness, and cardiac and kidney dysfunction.

3 Sep 2010

WaferGen launches SmartChip System for discovery, validation of biomarkers

WaferGen Biosystems, Inc., a leading developer of state-of-the-art genomic analysis systems, today announced it has launched the breakthrough WaferGen SmartChip Real-Time PCR System, the next-generation Real-Time PCR system for discovery and validation of biomarkers, or gene expression patterns, on a single platform. The SmartChip System is designed to provide accurate, highly sensitive and high-throughput gene expression profiling capabilities to researchers, clinicians and pharmaceutical companies.

6 Aug 2010

AdvanDx's 90 minutes protocol for Yeast Traffic Light PNA FISH test receives FDA 510(k) clearance

AdvanDx today announced that it has received FDA 510(k) clearance for a fast, 90 minutes protocol for its Yeast Traffic Light® PNA FISH® test. The faster protocol reduces the PNA FISH turn-around time from the original 2.5 hours to 90 minutes by reducing PNA probe hybridization from 90 minutes to 30 minutes.

30 Jul 2010

Circulating aberrant cells increase as non-small cell lung cancer progresses

A novel approach detects genetically abnormal cells in the blood of non-small cell lung cancer patients that match abnormalities found in tumor cells and increase in number with the severity of the disease, a research team led by scientists at The University of Texas MD Anderson Cancer Center report in the journal Clinical Cancer Research.

23 Jul 2010

New technique to detect abnormal cell circulation in non-small lung cancer

Researchers at The University of Texas M. D. Anderson Cancer Center are testing a new technique for identifying circulating genetically abnormal cells, which can lead to poor prognosis, in patients with non-small cell lung cancer.

23 Jul 2010

SeqWright, RainDance Technologies partner to offer RainStorm microdroplet-based PCR technology

SeqWright Inc., a world-wide leader in custom genomic and molecular biology services, announced today the expansion of its service portfolio by partnering with RainDance Technologies to offer the company's innovative RainStorm™ microdroplet-based PCR technology. SeqWright recognizes the growing demand from life science researchers for more efficient and cost-effective processes that allow for automated workflows providing greater confidence in results to meet the needs of large-scale resequencing studies.

30 Jun 2010

OvaGene Oncology opens new advanced molecular research and clinical laboratory facility

OvaGene Oncology Inc., a biotechnology company specializing in the development and commercialization of personalized DNA-based diagnostics for gynecologic cancer, announced today the opening of its new clinical and research laboratory in Irvine, California. This state-of-the-art facility will serve as the central headquarters for operations, research, and molecular clinical lab testing.

23 Jun 2010

Dako, Omnyx partner to develop clinical algorithms for digital pathology

Dako, a Danish-based world leader in tissue-based cancer diagnostics, and Omnyx, a leader in digital pathology solutions, announced today that they have entered into a three-year agreement to develop clinical algorithms for digital pathology. The aim is to support pathologists in generating even more accurate, objective and reproducible diagnostic results.

21 Jun 2010

CGH, FISH techniques effective for postmortem analysis of fetuses, infants with congenital anomalies

New techniques to detect chromosomal abnormalities can offer a higher degree of accuracy. Chromosomal abnormalities are a well-known cause of multiple congenital anomalies, and conventional methods of culture analysis have proven unsuccessful in 10% to 40% of cases. Comparative genomic hybridization (CGH) and fluorescent in situ hybridization (FISH) techniques were tested and found successful by analyzing tissue from children who had multiple congenital anomalies.

9 Jun 2010

Quintiles announces comprehensive suite of PI3K biomarker assays

Quintiles today announced a comprehensive suite of biomarker assays to help biopharmaceutical companies investigate the phosphoinositide 3-kinases (PI3K) cancer survival pathway, the focus of numerous anti-cancer therapies under development. Understanding the PI3K pathway is essential in developing new medicines to inhibit or block this pathway, thereby cutting off a metabolic function needed for certain cancers to survive.

8 Jun 2010

Infinity announces Phase 2 clinical trial results of IPI-504 for NSCLC

Infinity Pharmaceuticals, Inc. today reported the results from its Phase 2 clinical trial of IPI-504, the company's i.v.-administered Hsp90 chaperone inhibitor, in patients with advanced non-small cell lung cancer (NSCLC). Data reported show that IPI-504 demonstrated clinical activity in patients with NSCLC, in particular among patients with oncogenic anaplastic lymphoma kinase (ALK) gene rearrangements.

4 Jun 2010

A unique multi-modal atlas of human brain

The Allen Institute for Brain Science announced today that it has launched the Allen Human Brain Atlas, a publicly available online atlas charting genes at work throughout the human brain.

25 May 2010

Biocept granted US patent for cell separation technology using microfluidic device

Biocept, Inc., an emerging leader in rare cell capture, announced today that the U.S. Patent and Trademark Office has issued a patent for Biocept's cell separation technology using a microfluidic device. U.S. patent #7,695,956 entitled "Device for Cell Separation and Analysis and Method of Using" protects Biocept's microflow device to isolate cells from a bodily fluid using a flow path where straight-line flow is interrupted by transverse posts arranged in a random pattern.

21 May 2010

Researchers develop new technology to manage prostate cancer treatment

Researchers at Queen's University have developed a new way of performing lab tests that could improve the way doctors manage prostate cancer treatment. It will allow them to identify with unprecedented accuracy losses of a gene called PTEN that is associated with an aggressive group of prostate cancers.

13 May 2010

DNA capture techniques enable sequencing of ancient Neandertal DNA

Researchers from the Max Planck Institute (MPI), Cold Spring Harbor Laboratory (CSHL), Agilent Technologies Inc., and other prestigious institutions worldwide have shown that DNA capture techniques can greatly enable the sequencing of ancient Neandertal DNA, providing new insight into the nature of these prehistoric hominids.

7 May 2010

BioDiscovery signs OEM Agreement with Exiqon

BioDiscovery, Inc., a leader in integrated software solutions for microarray-based research, and Exiqon A/S, a leader in microRNA analysis products and services, announced today an OEM Agreement incorporating BioDiscovery's array analysis and visualization software with Exiqon's arrays.

5 May 2010

Protein test to determine response of lung cancer patients to erlotinib

Testing for the presence of specific cancer protein 'fingerprints' in the blood of lung cancer patients may be a useful means of identifying a subgroup whose tumors are more likely to shrink when treated with the drug erlotinib, especially when other testing methods are unavailable, according to new data presented at the 2nd European Lung Cancer Conference in Geneva, Switzerland.

3 May 2010

MMRC Multiple Myeloma Genomics Initiative presented at AACR 2010

An analysis of 38 myeloma tumor genomes surveyed through extensive next-generation sequencing by the Broad Institute has revealed intriguing recurrent mutations that point to important cellular pathways which contribute to multiple myeloma. These data were revealed during an oral presentation entitled "First Impressions of the Multiple Myeloma Genome" by Todd R. Golub, MD, Director of the Cancer Program at the Eli and Edythe L. Broad Institute.

21 Apr 2010